Drug importation proposals threaten one drug maker more than others
States and others won’t be importing every single medicine — and some drug makers have far more to lose than others if the plans are finalized.
Related Articles
Sarepta reports second patient death after treatment with Duchenne gene therapy
Sarepta said it was halting shipments of its Duchenne gene therapy for patients who can no longer walk, following the death of a second recipient.
Get 50% off an annual STAT+ subscription
Join the STAT+ community today and enjoy unlimited access to award-winning journalism, premium data tools, discounted event tickets, and much more.
In fight over research overhead funding, universities propose alternatives to Trump’s cuts
Exclusive: Facing NIH cuts in “indirect cost” funding, universities float new models to streamline requests and ensure support for research overhead, labs, and federal grants.
The AMA is not properly representing physicians
Billing codes are just one way the American Medical Association has strayed from its core mission.
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
HHS plans ‘bold, edgy’ campaign on ultra-processed foods and diabetes
RFK Jr. is pursuing a “bold, edgy” “Take Back Your Health” campaign that will inveigh against ultra-processed food and seek to make health wearables “cool.”
Hospitals would be hit hardest by Medicaid cuts in GOP tax bill, report finds
To finance tax cuts, a GOP bill would reduce Medicaid payments to hospitals by $321 billion, hitting both blue and red states hard, a new…
STAT readers on animal models, sexual assault kits, and more
Is science ready to move away from animal models? STAT readers’ opinions vary.
3 Pivotal Biopharma Growth Drivers Reshaping 2025 and Beyond | June 17 in Boston
Dive into top trends shaping the biopharma industry with STAT and experts, who will share practical insights and forward-looking signals. June 17 – Join us…
Anne Wojcicki wins back 23andMe, this time as a nonprofit
23andMe, which became a household name for its genetic testing services, is set to emerge from bankruptcy as a nonprofit.